Hasmik Ghazinian
Overview
Explore the profile of Hasmik Ghazinian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eslam M, Fan J, Yu M, Wong V, Cua I, Liu C, et al.
Hepatol Int
. 2025 Feb;
PMID: 40016576
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association...
2.
Choudhury A, Kulkarni A, Arora V, Soin A, Dokmeci A, Chowdhury A, et al.
Hepatol Int
. 2025 Feb;
19(1):1-69.
PMID: 39961976
Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus report of the...
3.
Pan Z, Derbala M, AlNaamani K, Ghazinian H, Fan J, Eslam M
Ann Hepatol
. 2024 May;
29(5):101512.
PMID: 38710473
Introduction And Objectives: Fatty liver disease is a multisystem disease. Metabolic dysfunction-associated fatty liver disease (MAFLD) is a more accurate indicator of chronic kidney disease (CKD) than nonalcoholic fatty liver...
4.
Maiwall R, Pasupuleti S, Choudhury A, Kim D, Sood A, Goyal O, et al.
Hepatol Int
. 2022 Dec;
17(3):662-675.
PMID: 36571711
Background And Aim: Acute-on-chronic liver failure (ACLF) is a severe form of alcoholic hepatitis (SAH). We aimed to study the natural course, response to corticosteroids (CS), and the role of...
5.
Alharthi J, Gastaldelli A, Cua I, Ghazinian H, Eslam M
Curr Opin Gastroenterol
. 2022 Feb;
38(3):251-260.
PMID: 35143431
Purpose Of Review: In 2020, a novel comprehensive redefinition of fatty liver disease was proposed by an international panel of experts. This review aims to explore current evidence regarding the...
6.
Lau G, Yu M, Wong G, Thompson A, Ghazinian H, Hou J, et al.
Hepatol Int
. 2022 Jan;
16(2):486-487.
PMID: 35076895
No abstract available.
7.
Lau G, Yu M, Wong G, Thompson A, Ghazinian H, Hou J, et al.
Hepatol Int
. 2021 Aug;
15(5):1031-1048.
PMID: 34427860
Background & Aim: Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical...
8.
Verma N, Dhiman R, Singh V, Duseja A, Taneja S, Choudhury A, et al.
Hepatol Int
. 2021 Jun;
15(3):753-765.
PMID: 34173167
Background: Multiple predictive models of mortality exist for acute-on-chronic liver failure (ACLF) patients that often create confusion during decision-making. We studied the natural history and evaluated the performance of prognostic...
9.
Fouad Y, Lazarus J, Negro F, Peck-Radosavljevic M, Sarin S, Ferenci P, et al.
Aliment Pharmacol Ther
. 2021 Mar;
53(10):1080-1089.
PMID: 33751604
Background: The World Health Organization (WHO) set a goal to eliminate hepatitis C (HCV) infection globally by 2030, with specific targets to reduce new viral hepatitis infections by 80% and...
10.
Maiwall R, Bajpai M, Choudhury A, Kumar A, Sharma M, Duan Z, et al.
Liver Int
. 2021 Feb;
41(5):1083-1096.
PMID: 33529450
Background And Aim: Plasma-exchange (PE) has improved survival in acute liver failure by ameliorating systemic inflammatory response syndrome (SIRS). We evaluated PE and compared it to Fractional Plasma Separation and...